Polaryx Therapeutics PLYX
NASDAQ PLYX
$1.94 +0.00 (+0.00%)
At close: Oct 22, 2026 · 4:00 PM EDT

Polaryx Therapeutics (PLYX) Return on Equity [ROE] (2026)

Updated

Polaryx Therapeutics (PLYX) reported Return on Equity [ROE] of -138.14% for Q2 2026.

Analysis

Polaryx Therapeutics (PLYX) Return on Equity [ROE] (2026) Analysis & Trends

For FY2025, Polaryx Therapeutics posted Return on Equity [ROE] of -168.61%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 19.33%
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn -
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn 7.21%
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 31.52%
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 21.39%
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 83.75%
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -18.38%
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn 4.97%
10 Polaryx Therapeutics 93.18 Mn 68.79 Mn - -138.14%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -138.14%
API Access

Polaryx Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=PLYX&period=max&api_key=YOUR_API_KEY